The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration of high doses of a carboxylic formulation containing both eicosapentaenoic acid and docosahexaenoic acid, but it did show an increase in risk of atrial fibrillation. In this interview, Steven E. Nissen MD, MACC; Stephen J. Nicholls MBBS, PhD, FACC; and Michael Mikolaj MD, MPH, FACC, discuss STRENGTH and whether omega-3 fatty acids produce net benefit or harm. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.